Management of Topiramate-Related Fever

Understanding Topiramate-Related Fever

• Topiramate has carbonic anhydrase inhibitor properties that can induce metabolic acidosis and impair sweating mechanisms, as reported by the American Gastroenterological Association 1, 2

Clinical Assessment

• Signs of metabolic acidosis, such as decreased serum bicarbonate levels, should be monitored in patients taking topiramate, according to the American Gastroenterological Association 1, 2

Management Algorithm

• For moderate to severe symptoms, active cooling measures should be implemented immediately, as recommended by the Society of Critical Care Medicine 3
• Topiramate should be tapered and discontinued, with a recommended dose reduction of taking 1 capsule every other day for at least 1 week before stopping completely, to minimize seizure risk, as suggested by the American Gastroenterological Association 1, 2

Special Considerations

• Patients with a history of kidney stones require extra caution when taking topiramate, as its carbonic anhydrase inhibition can increase the risk of nephrolithiasis, according to the American Gastroenterological Association 1

Common Pitfalls

• Misattributing fever to infection rather than medication effect is a common pitfall, as noted by the Society of Critical Care Medicine 3
• Failing to recognize the association between topiramate and impaired thermoregulation, and not considering metabolic acidosis as a potential complication, are also common pitfalls, as reported by the American Gastroenterological Association 1